Status:
COMPLETED
A Study of PEGASYS (Pegylated-interferon Alfa-2a) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Hepatitis C, Chronic
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This single arm study will provide treatment or re-treatment with PEGASYS as monotherapy or in combination with ribavirin (Copegus), to patients with chronic hepatitis C (CHC) who have participated in...
Eligibility Criteria
Inclusion
- Adult patients, ≥ 18 years of age.
- Chronic hepatitis C (CHC) patients with compensated liver disease (Child-Pugh A) who have participated in a donor protocol where access to treatment or re-treatment with PEGASYS monotherapy or in combination with Copegus was promised or deemed appropriate after completion of the donor protocol.
Exclusion
- Evidence of decompensated liver disease (Child B or C cirrhosis).
Key Trial Info
Start Date :
April 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2012
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00800735
Start Date
April 1 2009
End Date
March 1 2012
Last Update
October 30 2013
Active Locations (23)
Enter a location and click search to find clinical trials sorted by distance.
1
Sacramento, California, United States, 95817
2
San Francisco, California, United States, 94115
3
Lutherville, Maryland, United States, 21093
4
Manhasset, New York, United States, 11030